Merck has announced plans to acquire Cidara Therapeutics, the developer of a promising experimental flu treatment, in a deal valued at $9.2 billion.
Back
Merck has announced plans to acquire Cidara Therapeutics, the developer of a promising experimental flu treatment, in a deal valued at $9.2 billion.